Cavendish Selects Amarantus to Present at the Cavendish Global Health Impact Forum
March 26 2014 - 8:00AM
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology
company focused on the discovery and development of novel
diagnostics and therapeutics related to neurodegeneration and
apoptosis, announced today that it has been selected to present at
the Cavendish Global Health Impact Forum taking place May 5-7 in
New York, NY. The purpose of the Forum is to help family offices
and foundations develop and implement their individual pro-social
impact investing, grant-giving, and philanthropy programs within
health and the life sciences. To accomplish this mission the Forum
showcases presentations and panel discussions by leading
scientists, accomplished healthcare delivery professionals,
health-policy experts and the private-sector engaged in developing
innovations with the potential for transformational impact on
disease prevention, diagnosis and treatment.
Michael Moffat, Cavendish co-founder and President explains,
"With the help of our expert advisors, we conduct a global search
of research institutions and the private-sector in order to
identify organizations that meet the required standard of
scientific excellence. We believe the quality and originality
of Amarantus' research positions them to make a major contribution
to the diagnosis and treatment of Alzheimer's disease around the
world."
"We are honored to be selected to present at this unique event,
and it is further recognition of our innovative research and
discoveries which may lead to better diagnosis and treatment of
Alzheimer's," said Gerald Commissiong, President and CEO "We
welcome the chance to interact with many of the world's leading
scientific minds, thought-leaders and generous philanthropic
individuals and families who are all dedicated to the common cause
of improving the health and lives of people around the world.
Alzheimer's disease is a major worldwide problem, the research we
are conducting positions us to help solve one of the great health
challenges of our time."
Cavendish Global consists of over 150 leading family offices and
foundations from around the world with combined assets of over $190
billion who share a passion for
pro-social endeavors within health and the life sciences.
The Cavendish Global Health Impact Forum provides family
offices with a discrete, peer-to-peer knowledge expansion and
relationship building environment, combined with the information
and educational resources required by foundations actively
seeking to accelerate technological innovation and health access
through sustainable philanthropy, grant-making and impact
investing. The Forum is also an opportunity for family offices
to champion and share information on projects and organizations,
which they are passionate about with other family offices from
around the world. Cavendish Global together with the
Global Partnerships Forum and the New York Academy of
Sciences organizes the Forum annually in New York.
About Amarantus
Amarantus is a biotechnology company developing treatments and
diagnostics for diseases associated with neurodegeneration and
protein misfolding-related apoptosis. The Company has licensed
Eltoprazine ("Eltoprazine"), a phase 2b ready indication for
Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company
has an exclusive worldwide license to the Lymphocyte Proliferation
test ("LymPro Test(R)") for Alzheimer's disease and owns the
intellectual property rights to a therapeutic protein known as
Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is
developing MANF-based products as treatments for brain disorders.
Amarantus is a Founding Member of the Coalition for Concussion
Treatment (#C4CT), a movement initiated in collaboration with
Brewer Sports International seeking to raise awareness of new
treatments in development for concussions and nervous-system
disorders. The Company also owns intellectual property for the
diagnosis of Parkinson's disease ("NuroPro") and the discovery of
neurotrophic factors ("PhenoGuard"). For further information please
visit www.Amarantus.com, or connect with the Company on Facebook,
LinkedIn, Twitter and Google+.
About Cavendish Global
Cavendish Global provides family offices and their
foundations with a discrete, peer-to-peer knowledge expansion and
relationship building environment, combined with the innovative
resources required to help develop and implement their
individual pro-social impact investment, grant making and
philanthropy programs within health and the life sciences.
Cavendish Global provides family offices with a number of
innovative resources, which includes Cavendish Impact Forums.
A unique gathering of leading family offices, Cavendish
Impact Forums take place three times each year; in the United
States (taking place in New York at the United Nations
Headquarters May 5th to 7th 2014), Europe (Oxford University,
October 2014) and a third event held at a Cavendish Host
Partner City which moves to a different global location each
year (Dubai, UAE January 2015).
For more information: http://cavendishglobal.com
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements." These forward-looking statements
generally are identified by the words believes," project,"
expects," anticipates," estimates," intends," strategy," plan,"
may," will," would," will be," will continue," will likely result,"
and similar expressions. Forward-looking statements are based on
current expectations and assumptions that are subject to risks and
uncertainties which may cause actual results to differ materially
from the forward-looking statements. Our ability to predict results
or the actual effect of future plans or strategies is inherently
uncertain. Factors which could have a material adverse effect on
our operations and future prospects on a consolidated basis
include, but are not limited to: changes in economic conditions,
legislative/regulatory changes, availability of capital, interest
rates, competition, and generally accepted accounting principles.
These risks and uncertainties should also be considered in
evaluating forward-looking statements and undue reliance should not
be placed on such statements.
CONTACT: Investor/Media Contacts
Aimee Boutcher, Director of Investor Relations
Amarantus Bioscience Holdings, Inc.
408-737-2734 x 101
ir@amarantus.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024